Non-arteritic anterior ischemic and glaucomatous optic neuropathy: Implications for neuroretinal rim remodeling with disease severity.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 08 09 2022
accepted: 06 05 2023
medline: 22 5 2023
pubmed: 18 5 2023
entrez: 18 5 2023
Statut: epublish

Résumé

Post-acute non-arteritic ischemic optic neuropathy (NAION) and glaucomatous optic neuropathy (GON) can be difficult to differentiate clinically. Our objective was to identify optical coherence tomography (OCT) parameters to help differentiate these optic neuropathies. We compared 12 eyes of 8 patients with NAION and 12 eyes of 12 patients with GON, matched for age and visual field mean deviation (MD). All patients underwent clinical assessment, automated perimetry (Humphrey Field Analyzer II; Carl Zeiss Meditec, Dublin, CA, USA), and OCT imaging (Spectralis OCT2; Heidelberg Engineering, Heidelberg, Germany) of the optic nerve head and macula. We derived the neuroretinal minimum rim width (MRW), peripapillary retinal nerve fibre layer (RNFL) thickness, central anterior lamina cribrosa depth, and macular retinal thickness. MRW was markedly thicker, both globally and in all sectors, in the NAION group compared to the GON group. There was no significant group difference in RFNL thickness, globally or in any sector, with the exception of the temporal sector that was thinner in the NAION group. The group difference in MRW increased with increasing visual field loss. Other differences observed included lamina cribrosa depth significantly greater in the GON group and significantly thinner central macular retinal layers in the NAION group. The ganglion cell layer was not significantly different between the groups. The neuroretinal rim is altered in a dissimilar manner in NAION and GON and MRW is a clinically useful index for differentiating these two neuropathies. The fact that the difference in MRW between the two groups increased with disease severity suggests distinct remodelling patterns in response to differing insults with NAION and GON.

Identifiants

pubmed: 37200340
doi: 10.1371/journal.pone.0286007
pii: PONE-D-22-25051
pmc: PMC10194940
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0286007

Informations de copyright

Copyright: © 2023 Eadie et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Curr Opin Ophthalmol. 2003 Apr;14(2):86-90
pubmed: 12698048
Exp Eye Res. 2011 Aug;93(2):133-40
pubmed: 20708001
Prog Retin Eye Res. 2020 Jul;77:100840
pubmed: 31982595
Exp Eye Res. 2011 Aug;93(2):120-32
pubmed: 20849846
Prog Retin Eye Res. 2001 Sep;20(5):595-624
pubmed: 11470452
Eur J Ophthalmol. 2018 Nov;28(6):662-669
pubmed: 29564937
Acta Ophthalmol. 2018 Dec;96(8):e1018-e1024
pubmed: 30240137
Prog Brain Res. 2008;173:47-57
pubmed: 18929101
Br J Ophthalmol. 2017 Feb;101(2):143-149
pubmed: 27162227
Am J Ophthalmol. 1993 Jul 15;116(1):113-4
pubmed: 8328536
Am J Ophthalmol. 2021 Feb;222:277-284
pubmed: 32950510
Ophthalmology. 1999 Nov;106(11):2144-53
pubmed: 10571351
Exp Eye Res. 2019 Jun;183:88-97
pubmed: 30447198
Ophthalmology. 1991 May;98(5 Suppl):786-806
pubmed: 2062513
Ophthalmology. 2013 Mar;120(3):535-543
pubmed: 23265804
Prog Retin Eye Res. 2017 Mar;57:46-75
pubmed: 28012881
Can J Ophthalmol. 2009;44 Suppl 1:S7-93
pubmed: 19492005
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):4
pubmed: 32271888
BMC Ophthalmol. 2017 Jan 10;17(1):2
pubmed: 28073365
Br J Ophthalmol. 2014 Jul;98 Suppl 2:ii15-9
pubmed: 24357497
Ophthalmology. 2017 Sep;124(9):1392-1402
pubmed: 28461018
Ophthalmology. 2017 Dec;124(12S):S57-S65
pubmed: 29157363
Am J Ophthalmol. 2013 Aug;156(2):218-227.e2
pubmed: 23768651
Science. 1991 Nov 22;254(5035):1178-81
pubmed: 1957169
Curr Opin Ophthalmol. 1995 Apr;6(2):89-95
pubmed: 10150863
Exp Eye Res. 2017 Apr;157:13-19
pubmed: 28223180
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
Neuroophthalmology. 2019 Aug 21;44(2):76-88
pubmed: 32395154
Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1011-6
pubmed: 26962697
Ophthalmology. 1995 Feb;102(2):217-29
pubmed: 7862410
N Engl J Med. 2015 Jun 18;372(25):2428-36
pubmed: 26083207
Rom J Ophthalmol. 2018 Apr-Jun;62(2):138-143
pubmed: 30206557
Am J Ophthalmol. 2020 Oct;218:164-172
pubmed: 32574771
Invest Ophthalmol Vis Sci. 2011 Apr 14;52(5):2425-36
pubmed: 21493951

Auteurs

Brennan D Eadie (BD)

Department of Ophthalmology and Visual Sciences, Dalhousie University, and Nova Scotia Health Authority, Halifax, Canada.

Oksana M Dyachok (OM)

Department of Ophthalmology and Visual Sciences, Dalhousie University, and Nova Scotia Health Authority, Halifax, Canada.

Jack H Quach (JH)

Department of Ophthalmology and Visual Sciences, Dalhousie University, and Nova Scotia Health Authority, Halifax, Canada.

Charles E Maxner (CE)

Department of Ophthalmology and Visual Sciences, Dalhousie University, and Nova Scotia Health Authority, Halifax, Canada.

Paul E Rafuse (PE)

Department of Ophthalmology and Visual Sciences, Dalhousie University, and Nova Scotia Health Authority, Halifax, Canada.

Lesya M Shuba (LM)

Department of Ophthalmology and Visual Sciences, Dalhousie University, and Nova Scotia Health Authority, Halifax, Canada.

Jayme R Vianna (JR)

Department of Ophthalmology and Visual Sciences, Dalhousie University, and Nova Scotia Health Authority, Halifax, Canada.

Balwantray C Chauhan (BC)

Department of Ophthalmology and Visual Sciences, Dalhousie University, and Nova Scotia Health Authority, Halifax, Canada.

Marcelo T Nicolela (MT)

Department of Ophthalmology and Visual Sciences, Dalhousie University, and Nova Scotia Health Authority, Halifax, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH